Andersen Global udvider sin tilstedeværelse i Argentina med samarbejdsfirmaet Confis
24.1.2025 02:45:00 CET | Business Wire | Pressemeddelelse
Andersen Global udbygger sin tilstedeværelse i Argentina gennem en samarbejdsaftale med Confis, et skattefirma med base i Córdoba, der betjener kunder i hele landet og regionen.
Andersen har i øjeblikket en afdeling i Buenos Aires, som ledes af administrerende partner Cecilia Goldemberg. "Vi har været meget heldige at arbejde med teams som Confis, hvis services og kultur supplerer vores egen så godt, som de gør," fortæller Cecilia. "Vores kunder og medarbejdere mærker allerede fordelene."
Confis blev stiftet i 1997 og er en betroet rådgiver for virksomheder med aktiviteter på både nationale og internationale markeder. Firmaet tilbyder en bred vifte af tjenester, herunder skatterevision og -administration, virksomhedsfinansiering, skatte- og arbejdsmarkedsrådgivning, lønadministration, risikostyring og opstartsstøtte.
"Córdobas strategiske position som et industrielt og teknologisk knudepunkt understreger vigtigheden af at levere en skræddersyet lokal ekspertise og tilbyde omfattende skatte- og finansløsninger," siger stiftende partner Fernando Nestor. "Ved at investere i vores medarbejdere og samarbejde med Andersen Global forbedrer vi vores kapacitet til at levere effektive tjenester til vores kunder i og uden for Argentina."
Stiftende partner Gustavo Conforto tilføjer: "Denne alliance er en vigtig milepæl i udviklingen og styrkelsen af vores firmas kompetencer. Samarbejdet med Andersen Globals medlems- og samarbejdsfirmaer udvider vores serviceudbud og styrker vores position som en betroet aktør både lokalt og internationalt. Ved at blande Confis' dybdegående lokale ekspertise med Andersen Globals ressourcer er vores firma klar til at levere specialiserede, fremadrettede løsninger, der imødekommer de skiftende behov hos vores kunder i Argentina og andre steder."
"Den solide praksis hos Confis i Córdoba, den næststørste by i Argentina, og kvaliteten af deres medarbejdere passer perfekt til Andersen," siger Mark L. Vorsatz, bestyrelsesformand for Andersen Global og administrerende direktør for Andersen. "Med deres tilføjelse har vi nu en tilstedeværelse på dette vigtige marked og ser frem til et synergistisk samarbejde, der styrker vores evne til at levere omfattende skatteløsninger i hele regionen."
Andersen Global er en international sammenslutning af juridisk adskilte og uafhængige medlemsvirksomheder, der består af skattejurister samt skatte- og værdiansættelseseksperter i hele verden. Andersen Global, der blev etableret i 2013 af den amerikanske medlemsvirksomhed Andersen Tax LLC, har nu mere end 18.000 eksperter i hele verden og en tilstedeværelse på over 500 lokaliteter gennem sine medlemsvirksomheder og samarbejdsvirksomheder.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20250123952868/da/
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum